Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial.
Paton NI, Goodall RL, Dunn DT, Franzen S, Collaco-Moraes Y, Gazzard BG, Williams IG, Fisher MJ, Winston A, Fox J, Orkin C, Herieka EA, Ainsworth JG, Post FA, Wansbrough-Jones M, Kelleher P; Hydroxychloroquine Trial Team. Paton NI, et al. Among authors: dunn dt. JAMA. 2012 Jul 25;308(4):353-61. doi: 10.1001/jama.2012.6936. JAMA. 2012. PMID: 22820788 Free PMC article. Clinical Trial.
Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).
Gibb DM, Walker AS, Kaye S, De Rossi A, Ait-Khaled M, Pillay D, Muñoz-Fernandez MA, Loveday C, Compagnucci A, Dunn DT, Babiker AG. Gibb DM, et al. Among authors: dunn dt. Antivir Ther. 2002 Dec;7(4):293-303. Antivir Ther. 2002. PMID: 12553485 Clinical Trial.
Immunologic changes during unplanned treatment interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infection.
Gibb DM, Duong T, Leclezio VA, Walker AS, Verweel G, Dunn DT; Collaborative HIV Paediatric Study Steering Committee. Gibb DM, et al. Among authors: dunn dt. Pediatr Infect Dis J. 2004 May;23(5):446-50. doi: 10.1097/01.inf.0000122601.62358.74. Pediatr Infect Dis J. 2004. PMID: 15131469 Clinical Trial.
A randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children: the PERA (PENTA 8) trial.
Green H, Gibb DM, Compagnucci A, Giacomet V, de Rossi A, Harper L, Saïdi Y, Castelli-Gattinara G, Pillay D, Babiker AG, Aboulker JP, Lyall H, Bacheler LT, Walker AS, Debré M, Rosso R, Burger DM, Della Negra M, Dunn DT, Giaquinto C; Paediatric European Network for the Treatment of AIDS. Green H, et al. Among authors: dunn dt. Antivir Ther. 2006;11(7):857-67. Antivir Ther. 2006. PMID: 17302248 Clinical Trial.
Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir.
Ndembi N, Goodall RL, Dunn DT, McCormick A, Burke A, Lyagoba F, Munderi P, Katundu P, Kityo C, Robertson V, Yirrell DL, Walker AS, Gibb DM, Gilks CF, Kaleebu P, Pillay D; Development of Antiretroviral Treatment in Africa Virology Group and Trial Team. Ndembi N, et al. Among authors: dunn dt. J Infect Dis. 2010 Jan 1;201(1):106-13. doi: 10.1086/648590. J Infect Dis. 2010. PMID: 19938977 Clinical Trial.
Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children.
HIV Paediatric Prognostic Markers Collaborative Study; Boyd K, Dunn DT, Castro H, Gibb DM, Duong T, Aboulker JP, Bulterys M, Cortina-Borja M, Gabiano C, Galli L, Giaquinto C, Harris DR, HugheS M, McKinney R, Mofenson L, Moye J, Newell ML, Pahwa S, Palumbo P, Rudin C, Sharland M, Shearer W, Thompson B, Tookey P. HIV Paediatric Prognostic Markers Collaborative Study, et al. Among authors: dunn dt. AIDS. 2010 May 15;24(8):1213-7. doi: 10.1097/QAD.0b013e3283389f41. AIDS. 2010. PMID: 20386428
Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoring.
Lyagoba F, Dunn DT, Pillay D, Kityo C, Robertson V, Tugume S, Hakim J, Munderi P, Chirara M, Ndembi N, Goodall RL, Yirrell DL, Burke A, Gilks CF, Kaleebu P; DART Virology and Trial Team. Lyagoba F, et al. Among authors: dunn dt. J Acquir Immune Defic Syndr. 2010 Oct;55(2):277-83. doi: 10.1097/QAI.0b013e3181ea0df8. J Acquir Immune Defic Syndr. 2010. PMID: 20686411
132 results